 In an SEC filing, Soligenix Inc NASDAQ: SNGX disclosed that it cannot file its HyBryte marketing application in the U.S. in 1H of 2022. Citing COVID-19 related disruptions resulting in delays by the commercial active pharmaceutical ingredient manufacturer, the Company cannot provide the pre-requisite accrued stability data required to file the application. 